ASCO 2026 to Highlight Global Shift in Oncology Innovation with Increased Chinese Influence
The upcoming ASCO 2026 conference is set to showcase significant shifts in oncology innovation, with a notable increase in contributions from China. Analysts have observed that nearly one-third of presentations at last year's ASCO involved assets originating in China, highlighting a trend towards more globally distributed innovation. This shift is reshaping traditional assumptions in the pharmaceutical industry, as companies align research and development, communications, and commercial strategies earlier than before. The conference will explore how innovation, regulation, and commercialization are becoming interconnected across global markets, with China emerging as a key player in drug development and approval processes. 
